On July 2, Insilico Medicine rose 5.81% in regular trading, trading at HK$40.86/share, with turnover of HK$145 million. The stock opened over 10% higher before paring some gains.

On the news front, Insilico Medicine announced a global strategic collaboration agreement with Takeda Pharmaceutical. Under the agreement, the two companies will leverage Insilico's end-to-end Pharma.AI platform to jointly advance innovative drug candidates across multiple therapeutic areas selected by Takeda. Takeda will receive exclusive global rights to develop, manufacture, and commercialize the novel therapies identified through the collaboration.

Financially, Insilico will receive approximately $60 million in upfront and near-term milestone payments, with eligibility for additional preclinical, clinical, commercial, and sales-based milestones totaling up to approximately $600 million, plus tiered royalties on future net sales. This marks a significant validation of AI-driven drug discovery technology in partnership with a global pharmaceutical leader.

Notably, the stock had fallen 11.12% on June 30 due to heavy selling pressure from a major lock-up expiry, providing a lower base ahead of this catalyst.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)